| In Europe, Dr. Reddy’s is an emerging player in the generics space. Dr. Reddy’s Laboratories (UK) Ltd. was created through the acquisition of BMS Laboratories Ltd., and it’s wholly-owned subsidiary Meridian Healthcare, in April 2002. Within a short span of time, Dr. Reddy’s succeeded in taking a leading position in key genericized molecules. In other important markets like Italy, Spain, France, Nordic countries and the Netherlands, Dr. Reddy’s has partnered with established companies, thereby expanding its reach across the EU. |
The acquisition of Germany’s fourth largest generic company betapharm Arzneimittel GmbH has placed Dr. Reddy’s and its 500-strong Europe team on the fast-track to build on its business in the EU.
|
| Generics Market Growth & Penetration (2006) |
Market |
Total Pharma Mkt,
€ Mn |
Growth % |
Generics Mkt, € Mn |
Growth % |
Generics Mkt Share % |
| Germany |
22,080 |
3 |
4,780 |
6 |
21.6% |
| UK |
12,700 |
4 |
1,570 |
17 |
8.0% |
| Italy |
11,910 |
2 |
420 |
19 |
3.5% |
| Spain |
8,920 |
7 |
540 |
15 |
6.1% |
| France |
19,590 |
2 |
1,570 |
17 |
8.0% |
| Portugal |
2,420 |
5 |
350 |
18 |
14.6% |
| Source: Research Reports |
|
| |
|
|
| Generics Brochure |
 |
|
| Sustainability Report |
 |
|
| |
| |
| |
|
